Background-Left ventricular noncompaction (LVNC) is a genetically and phenotypically heterogeneous disease and, although increasingly recognized in clinical practice, there is a lack of widely accepted diagnostic criteria. We sought to identify novel genetic causes of LVNC and describe genotype-phenotype correlations. Methods and Results-A total of 190 patients from 174 families with left ventricular hypertrabeculation (LVHT) or LVNC were referred for cardiac magnetic resonance and whole-exome sequencing. A total of 425 control individuals were included to identify variants of interest (VOIs). We found an excess of 138 VOIs in 102 (59%) unrelated patients in 54 previously identified LVNC or other known cardiomyopathy genes. VOIs were found in 68 of 90 probands with LVNC and 34 of 84 probands with LVHT (76% and 40%, respectively; P<0.001). We identified 0, 1, and ≥2 VOIs in 72, 74, and 28 probands, respectively. We found increasing number of VOIs in a patient strongly correlated with several markers of disease severity, including ratio of noncompacted to compacted myocardium (P<0.001) and left ventricular ejection fraction (P=0.01). The presence of sarcomeric gene mutations was associated with increased occurrence of late gadolinium enhancement (P=0.004). Conclusions-LVHT and LVNC likely represent a continuum of genotypic disease with differences in severity and variable phenotype explained, in part, by the number of VOIs and whether mutations are present in sarcomeric or nonsarcomeric genes. Presence of VOIs is common in patients with LVHT. Our findings expand the current clinical and genetic diagnostic approaches for patients with LVHT and LVNC.
L eft ventricular noncompaction (LVNC) is a disorder of the heart characterized by a 2-layered myocardium consisting of compacted and noncompacted segments, prominent ventricular trabeculations, and intertrabecular recesses. 1 LVNC is increasingly recognized in clinical practice with a reported prevalence of 1:5000 individuals in the general population and 3% to 4% of adults with heart failure although this is likely an underestimate. 2 Patients with LVNC are at increased risk to develop heart failure, atrial and ventricular arrhythmias, and systemic embolic events, both in pediatric and adult populations. There is an ongoing debate about whether LVNC can be labeled as a distinct cardiomyopathy or simply as a trait shared by other primary cardiomyopathies. [3] [4] [5] [6] [7] The American Heart Association classified LVNC as a distinct primary cardiomyopathy. 8 However, the European Society of Cardiology has designated LVNC as an unclassified cardiomyopathy and does not take a firm stance on whether LVNC is a separate cardiomyopathy or a morphological trait. 9 One of the key issues underpinning this debate is the paucity of data on specific genotype-phenotype correlations. 10, 11 Numerous echocardiographic criteria have been proposed for diagnosing LVNC. However, poor correlation between these criteria has been reported. 12 Cardiac magnetic resonance (CMR) depicts appearance of the myocardium with excellent quality, and its role in diagnosing LVNC is increasing. [13] [14] [15] LVNC is currently thought to be a genetically heterogeneous, monogenic disease with autosomal dominant, autosomal recessive, and X-linked forms reported. [16] [17] [18] The mechanism responsible for the LVNC phenotype remains unclear but is thought to be related to abnormal cardiac embryogenesis with the majority of cases being familial or genetically triggered. [19] [20] [21] [22] The LVNC phenotype has been linked to mutations in sarcomeric genes in 30% of cases and Z-disc, cytoskeletal, and mitochondrial genes in the remainder. 3, 16, [23] [24] [25] Herein, we describe the largest cohort of consecutive subjects with left ventricular hypertrabeculation (LVHT) or LVNC undergoing CMR and whole-exome sequencing (WES) in an attempt to better correlate genotype and phenotype for this patient population.
Methods Patients
Between January 2013 and December 2013, we prospectively enrolled 190 patients from 174 families with suspected or known LVNC on the basis of clinical presentation (history, symptoms, ECG, presence of neuromuscular disease, and familial occurrence of LVNC) and transthoracic echocardiographic documentation of a distinct 2-layered structure of noncompacted and compacted left ventricular (LV) myocardium. In an attempt to capture patients with borderline expression of the disease, no arbitrary echocardiographic threshold for LVNC diagnosis was applied. Only patients ≥7 years of age with the ability to hold their breath were included in the study. The study was approved by the local institutional ethics committees (institutional review board), and written informed consent was obtained from each subject and assent from pediatric subjects.
Clinical Data Collection
At initial presentation, the following clinical characteristics were collected: (1) presence and nature of cardiac symptoms, (2) reason for referral, (3) presence of concomitant neuromuscular disorders, and (4) family history. Previous medical history was reviewed on all subjects. The initial clinical evaluation was performed without knowledge of genotype status.
Cardiac MRI
All CMR examinations were performed on a 1.5T clinical scanner (Signa HDxt, GE Healthcare, Milwaukee, WI) with standard acquisition methods to acquire cine and delayed enhancement images. Images were analyzed with commercial software (Qmass MR, Medis Medical Imaging Systems, Leiden, The Netherlands) by an experienced observer blinded to the patients' profiles. The 17-segment model of LV segmentation was used, 26 and the presence of any degree of trabeculation/noncompaction was assessed in every LV segment. A segment was considered as noncompacted if a distinct 2-layered appearance of trabeculated and compacted myocardium could be visually identified. For the segment with the most pronounced trabeculations, the maximal ratio of noncompacted to compacted myocardium (NC/C) was calculated. According to generally accepted CMR criteria proposed by Petersen et al, 13 NC/C ratio >2.3:1 was considered diagnostic for LVNC. Subjects who failed to meet these criteria but were otherwise suspected of having LVNC were labeled as having LVHT. Details on imaging protocol and data analysis are provided in the Data Supplement.
DNA Library Preparation, Capture Enrichment, and Sequencing
Libraries were constructed into Illumina paired-end pre-capture libraries according to the manufacturer's protocol (Illumina Multiplexing_SamplePrep_Guide_1005361_D) with modifications as described in the Baylor College of Medicine Human Genome Sequencing Center protocol (https://www.hgsc.bcm.edu/content/ protocols-sequencing-library-construction).
Primary Sequence Data Analysis and Variant Enrichment
Initial sequence analysis was performed using the Human Genome Sequencing Center Mercury analysis pipeline. In addition, variants were filtered if they had a minor allele frequency >0.5% (averaged from Thousand Genomes, Exome Aggregation Consortium, and Exome Sequencing Project), >1% if they had been previously associated with disease (The Human Gene Mutation Database), or >2% if the variant was homozygous or there was a second variant in the gene. Variants were removed from consideration if they were annotated as benign or likely benign in ClinVar from multiple laboratories. Variants were prioritized based on function and disease association (for details, see Data Supplement). Analysis was conducted separately for each member in a family. We computationally examined a control cohort of 425 unselected European individuals to identify variants, obtained from the Atherosclerosis Risk in Communities study, 27 which met our criteria for variants of interest (VOIs) in 2 different gene sets: a set of well-characterized known LVNC genes 28 ( 
Results

Study Participants
A total of 190 patients from 174 families were enrolled. After nonproband family members were removed, genotype-phenotype correlations were analyzed in the cohort of 174 probands (123 men). The mean age of probands was 26±16 years (range, 7-72). Seventy-nine subjects (45%) were <18 years of age. All patients successfully underwent CMR imaging and WES of their genomic DNA. Baseline characteristics are presented in Table 1 .
Genetic Variants
We found 138 rare, protein-altering variants in 54 previously identified LVNC or other known cardiomyopathy genes in 102 probands (59%), which were likely contributory to the patient phenotype (Table 2; Table III in the Data Supplement).
Twenty-six of the 54 identified cardiomyopathy genes were found to be mutated in ≥2 subjects with TTN, MYH7, MYPN, and LDB3 mutated in ≥6 patients each ( Figure IA in the Data Supplement), although when controlling for transcript length, the most enriched genes were TPM1, LDB3, and MYOZ2 ( Figure IB in the Data Supplement). We identified a strong enrichment for truncating mutations in TTN, RBM20, and MYH7 when compared with control and other disease cohorts although truncating mutations in MYH7 are generally considered not to be disease causing. 29 Forty-six of 54 identified cardiomyopathy genes did not have a previously established link with LVNC (Table I in the Data Supplement) although 16 of these genes have been associated with skeletal myopathy or cardiac dysfunction. Although it is difficult to assess the functional effects and potential pathogenicity of nonsynonymous variants, in a number of these genes (FLNC, KCNQ1, FKTN, MTMR14, MYLK2, RBM20, TBX20, PRKAR1A, and MEF2A), the identified variants were rare, previously identified as disease causing and predicted deleterious. Thus, these mutations have high potential of proving pathogenic, and it is likely that the subject's cardiac phenotype was associated with the genotype.
When considering only the well-characterized set of LVNC genes, we observed a modest increase in the number of individuals in our cohort with VOIs when compared with our control group (20.35%-21.5%; P=0.74; Fisher exact test). A greater enrichment was found using the cardiomyopathy gene set, with approximately double the number of individuals having at least 1 VOI. This effect was enhanced to ≈5-fold difference when considering only loss of function mutations ( Figure IIA in the Data Supplement). The distribution of VOIs in cardiomyopathy genes was significantly different between the cohort and the control (P=0.01). The disease cohort was also significantly enriched for multiple VOIs in individual patients; ≈1.7 as many patients had at least 1 VOI in our disease cohort, but 4.2× as many individuals had ≥2 VOIs ( Figure  IIB in the Data Supplement). Copy number analysis was performed from the WES data using XHMM, 30 and no high confidence copy number variants were identified in known cardiomyopathy genes.
Genotype-Phenotype Correlations
There were no significant differences between subjects with and those without VOIs with respect to age, sex, familial occurrence of LVNC, or New York Heart Association functional class (Table 1) .
When compared with patients with zero VOIs, patients with ≥1 VOIs had lower LV ejection fraction (LVEF), higher number of noncompacted LV segments, higher NC/C ratio were more likely to have neuromuscular disease, affected LV basal segments, late gadolinium enhancement (LGE), and CMR confirmatory diagnosis of LVNC (67% versus 31%; P<0.001).
In total, 90 of 174 probands (52%) met current CMR criteria for LVNC. 13 The remaining 84 probands were classified as LVHT. VOIs were identified significantly more frequently in the LVNC group as compared with the LVHT group (76% versus 40%; P<0.001).
Twenty-seven subjects were found to have VOIs in the conservative set of LVNC genes reported in the Online Mendelian Inheritance in Man database (Table IV in the Data Supplement). Presence of VOIs in these genes was associated with several markers of disease severity, including higher NC/C ratio (P=0.01) and more frequent occurrence of LVNC (P=0.004) and LGE (P=0.001) as compared with 75 subjects with VOIs in non-Online Mendelian Inheritance in Man LVNC genes and other known cardiomyopathy genes. In 28 probands, ≥2 variants met our criteria for being interesting (2, 3, and 4 VOIs found in 21, 6, and 1 patients, respectively). For the patient with 4 VOIs, all 4 variants were shared with an affected sibling. For further analyses, the entire cohort was divided into 3 subgroups on the basis of the number of VOIs (0, 1, and ≥2 VOIs, respectively; Table 3 ). A higher number of VOIs was correlated with higher NC/C ratio and lower LVEF (Figure 1 ). Several VOIs were also correlated with LV end-systolic volume index, number of noncompacted LV segments, affected LV basal segments, rates of CMR confirmatory diagnosis of LVNC, and presence of LGE.
Sarcomere Versus Nonsarcomere Genes
VOIs in either sarcomeric or nonsarcomeric genes were found in 39 and 47 unrelated patients, respectively, with 16 subjects having mutations in both sarcomeric and nonsarcomeric genes. The presence of sarcomeric gene mutations was associated with more frequent occurrence of trabeculations in the interventricular septum (P=0.01) and LGE, likely indicating fibrosis of the myocardium (P=0.004; Table 4 ). There was a nonsignificant trend toward lower LVEF and higher number of noncompacted LV segments among patients with sarcomeric gene mutations as compared with patients with nonsarcomeric gene mutations (both P=0.07).
Long-QT Syndrome Genes
Our initial screening identified a homozygous variant in KCNE1, a heterozygous frameshift mutation in KCNQ1, and a heterozygous variant in SCN5A, a known LVNC gene. 31 All these genes are known causes of long-QT syndrome (LQTS). We investigated whether other known diseasecausing or highly likely deleterious variants occurred in our cohort in other LQTS genes (Table V in the Data Supplement ) but used a less stringent minor allele frequency cutoff of 1%. We found a significant number of subjects with variants in KCNH2 (n=4; P=0.03 compared with control cohort). All variants had a minor allele frequency of 0, and of these, 3 were previously described as disease causing and the remaining variant was proximal (3 amino acids distant) from a previously described disease mutation. Although the mechanism by which mutations in KCNH2 might cause LVNC is unclear, the data show clear enrichment of rare variants in this gene when compared with a large population database, as well as an arrhythmia cohort (2.2% versus 0.6% and 0.8%, respectively). 32 Nine additional variants (10 total) were found in SCN5A, of these 7 were identical (p.P1973A) LGE NMD and were significantly enriched over the expected population frequency (1.84% versus 0.2%; P<0.001). One subject with the clinical phenotype of LVNC and LQTS type 3 was found to have 2 variants in SCN5A and an additional variant in TPM1. The clinical course has been significant for cardiac arrest secondary to ventricular tachycardia with subsequent implantable cardioverter defibrillator placement, and the patient was awaiting heart transplant secondary to end-stage heart failure.
Discussion
We identified at least 1 VOI in 59% of our cohort subjects in 54 different cardiomyopathy genes. Multiple variants were found in genes not previously reported in association with LVNC, including LQTS genes (KCNH2, KCNE1, KCNQ1, and KCNJ2), the cardio-and muscular myopathy gene FLNC, and MEF2A, which is associated with premature coronary artery disease. In many cases, these novel associations were made to genes harboring rare, highly deleterious, often previously described as disease causing, mutations in autosomal dominant genes; molecular diagnoses consistent with the contention that the subject either has or is likely to develop the disease. These findings underscore the diversity of genes already associated with LVNC and offer insight into varying clinical phenotypes associated with LVNC. Mutations in SCN5A have been previously reported to result in dilated cardiomyopathy and LQTS, 33 and our results indicate that other LQTS genes may also result in cardiomyopathy phenotypes. Although the mechanism for this is unclear, several hypotheses have been proposed including direct protein-protein interaction of the LQTS gene with the sarcomere or that LVNC is an acquired adaptive remodeling feature in response to impaired conduction. It is also possible that there is an underlying mutation driving the LVNC phenotype and mutations in LQTS genes act epigenetically to modify the penetrance or expressivity of the phenotype. Whatever the mechanism, our data show a strong enrichment for mutations in these genes when compared with control cohorts. 32 We identified 14 probands with truncating mutations in TTN in our cohort, firmly establishing the importance of this gene to LVNC. 34 Truncating mutations in TTN have been reported in association with dilated cardiomyopathy; however, there was no evidence of LVNC in their cohort. 35 We identified 14 probands with truncating TTN mutations and 8 had reduced LVEF. Mutations were identified in both the A disc and I band regions of titin, but there were no differences in NC/C ratio or LVEF between the 2 subgroups. Although truncating mutations in titin can be abrogated by alternate splicing, 11 of the 14 unique truncating mutations identified in this study occurred in constitutive exons (Table VI in the Data  Supplement) . Interestingly, across our cohort, titin showed significant (P=0.01) enrichment for co-occurrence with other VOIs, suggesting that additional mutational burden is required to develop a phenotype.
Twenty-eight unrelated patients had ≥2 or more identified VOIs. We found increased mutational burden in these genes between our LVNC cohort and an unselected population. Evidence for a mutational burden has also been reported for neuropathy and oligogenic inheritance in a family with hypertrophic cardiomyopathy. 36, 37 Strong correlations were found between mutational burden in individual patients and cardiac phenotypes, including NC/C ratio, number and distribution of noncompacted LV segments, LVEF, and presence of LGE. Interestingly, the probability of meeting current CMR criteria for LVNC was strongly associated with the number of VOIs. Multiple mutations, which alone are benign, have been shown to elicit a severe phenotype when present in combination, 38 in a similar way our findings indicate that LVNC may be caused by, or the phenotype exacerbated by, multiple, uncommon variants that act in a synergistic manner. This, in part, could explain the tremendous clinical heterogeneity of this disease specifically related to the presence or absence of ventricular dysfunction and remodeling, as well as the presence or absence of arrhythmia burden. This finding also potentially bridges the gap between the clinical diagnosis of LVNC and LVHT.
In 41% of subjects in our cohort, no VOI was found. This suggests that there are other causes of LVNC that are not captured by a WES approach. Such causes may include hitherto unrecognized LVNC/cardiomyopathy genes and variants which our analysis incorrectly determined were not pathogenic. Such variants may appear benign (eg, synonymous variants) but impact transcription, translation, or the function of the protein alone or in conjunction with other variants, or environmental factors, although the relatively young age of onset for the cohort implicate a genetic cause of LVNC in these cases. WES, typically, does not interrogate the intronic or untranslated regions of genes, nor intergenic regions, and is limited in its ability to detect copy number variants, all of which may contribute to the genetic landscape of LVNC. These latter challenges can be better addressed by wholegenome sequencing; however, interpretation of noncoding variants will remain challenging for the foreseeable future.
The term LVHT has traditionally been used to describe an increased number of trabeculations with normal histological appearance and was considered as a normal anatomic variant. 4 However, a distinction between LVNC and LVHT is often extremely difficult because there is a continuum from normal, hypertrabeculated myocardium to pathological appearance of the LV myocardium. In our study, we found presence of VOIs to be common (40%) in patients with LVHT. We also found that the NC/C ratio was directly correlated with the number of VOIs. Thus, there is a continuum of clinical expression, and the distinction between LVHT and LVNC may not be clinically relevant. The presence of LVHT warrants careful, longitudinal surveillance for change in clinical status.
The potential prognostic implications of LVHT and LVNC in patients with nonischemic dilated cardiomyopathy have been recently studied. 39 The authors reported that the presence of trabeculations had no influence on a variety of clinical outcomes. Although we did not assess these end points, our study suggests that the presence of LVHT/LVNC strongly impacts LV systolic function and fibrosis burden, both of which have been previously reported to result in increased mortality in the setting of LVNC. [40] [41] [42] Our data argue in favor of LVNC being a phenotype shared by different cardiac diseases and suggest that the presence of VOIs directly influences not only the morphological findings used currently for diagnosis but also LV systolic dysfunction and fibrosis burden. Based on our data, the use of currently promoted CMR diagnostic criteria may result in many patients failing to be appropriately diagnosed even though they harbor pathogenic mutations and may benefit from genetic testing. This would include interrogating all known cardiomyopathy genes, or all genes using WES, to give a clearer picture of the genetic burden than achieved testing the smaller number of known LVNC genes.
Limitations
A challenge to our study is the lack of consensus regarding criteria for LVNC and by including patients with LVHT we may confound our findings. Furthermore, a proportion of normal adults may show significant NC/C ratios in at least 1 region. 43 Nevertheless, to increase pre-test probability of having LVNC, both imaging and clinical data were used. 44 Our approach of including patients with LVHT was intentional to assist in deconstructing the current diagnostic approach, and our data support the continuum concept of disease. We also recognize that the LVNC phenotype may be secondary to causes other than genetic triggers, for example, unfavorable LV remodeling. 7, 45 With this in mind, we recognize that our study does not have longitudinal data and that we cannot document presence or absence of LV trabeculations early in life in our cohort. Although numerous potentially contributory mutations were identified using strict criteria (population conservation, evolutionary conservation, and known deleteriousness of the variant, gene function), these variants may still not be disease causing. 32 Functional methods of validation can be laborious and expensive and cannot be conducted on every novel variant. In the future, as sequencing becomes more ubiquitous, discovery of identical variants in multiple unrelated subjects with LVNC or LVHT may become the best method for determining pathogenicity.
Conclusions
Our study identifies potentially causative variants in multiple genes not previously implicated in LVNC, including truncating mutations in titin, an important cardiomyopathy and muscular dystrophy gene. The phenotype of LVNC may be influenced by the co-occurrence of multiple genetic mutations interacting epistatically. The severity of cardiac involvement, including degree of noncompaction and LV systolic dysfunction, is more pronounced in the presence of increasing number of VOI, consistent with a mutational burden hypothesis. Although sarcomeric genes may be responsible for LVNC, other genetic triggers, such as nonsarcomeric genes, may exist that result in the cardiac phenotype. Presence of VOIs is common in patients with LVHT and may represent partial expression of LVNC. LVHT and LVNC may represent a continuum of genotypic disease, with LVHT possibly representing a less advanced form that also warrants careful, longitudinal surveillance. Multiple family members and subjects with simultaneous presence of mutations in both nonsarcomere and sarcomere genes were excluded. CMR indicates cardiac magnetic resonance; DCM, dilated cardiomyopathy; LGE, late gadolinium enhancement; LV, left ventricle; LVEDVI, left ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction; LVESVI, left ventricular end-systolic volume index; LVNC, left ventricular noncompaction; and NC/C, ratio of noncompacted to compacted myocardium.
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